Many basic and clinical studies show erectile dysfunction (ED) to be caused by a wide variety of factors. Although these factors can be divided into psychological and organic origins and these too can further be subdivided, many patients will show complex patterns of causes for ED ('mixed ED'). Many of these factors will have a direct or indirect impact on the efficacy of centrally and peripherally acting drugs, thus necessitating a variety of drugs with different modes of action and different modes of application to ensure appropriate therapy for many patients. However, some factors will render all imaginable forms of pharmacological options totally inefficient, thus necessitating forms of treatment other than pharmacotherapy.
Introduction
As early as 1863, Eckard 1 used modern neurourological techniques to evaluate the erectile phenomenon. Although his pioneering studies were followed by many other excellent studies at different sites, Sigmund Freud's theory on the almost exclusive psychogenic origin of erectile dysfunction (ED) predominated the concept of this disease until the 1960s. Then, the subsequent introduction of therapeutic options for organogenic ED, such as penile prostheses, revascularization procedures, intracavernous injections, and various orally available drugs, paved the way for today's concept of organogenic (often mixed with psychogenic) origins. These new therapeutic options also led to a Gold Rush-like enthusiasm in this urological subspecialty. In the last 20 y, advanced physiological, pharmacological, and molecular biological studies broadened and sharpened our vision on the erectile process and its pathological conditions.
In contrast to this dramatic increase in basic knowledge, the diagnostic approach for ED is still in its scientific infancy. Duplex sonography of the penile arteries after pharmacostimulation was introduced in 1985, 2 but there is no international consensus on the drug and dose to use or on the time point to measure the parameters. In addition, no sufficient control studies have been performed in men with normal erectile function. A broad international consensus based on solid data obtained by strict scientific studies is urgently needed to determine other diagnostic tools to use in the treatment of ED.
Furthermore, scientifically valid information on the origin of ED, both in an individual patient and in a broader series, is difficult to obtain, since currently most patients receive treatment in a trial-and-error fashion without detailed diagnosis that would allow identification of possible causes and thus patientbased individualized therapy. Therefore, most academic studies and almost all phase 2 and 3 studies classify patients according to questionnaires that recall more ballpark guessing than appropriate workup.
These factors cause this article to be based on individual evaluations of series of patients (however, often evaluating large patient collectives) rather than on broad epidemiological studies.
Psychogenic ED
The investigation of the psychological causes of EDs has stagnated during the last 15 y. Although in most publications somatic factors are accurately differentiated into vascular, myogenic, and nerve or hormone components, psychogenic impotence, which is mostly defined by exclusion, is often treated as a monolithic block without differentiation. 3 After a period of turf wars about the ratio of organic vs psychogenic impotence, the pendulum seems to be swinging back to the opinion that most patients with erectile failure exhibit both organic and psychogenic factors. Few clinicians, if any, will object to a statement such as this, but as yet it remains unclear what this really means. The important and influential National Institutes of Health (NIH) consensus statement on impotence conveys the impression that psychological factors are merely contributors to erectile failure, whereas 'most patients are thought to demonstrate an organic component.' Other statements in the NIH report concerning psychogenic ED are rather vague, but the report does imply that we know how psychogenic causation functions and that better studies about treatment approaches are needed. I strongly disagree with this notion and suggest that we know very little about psychogenic ED and are just beginning to ask the right questions. In his comment on the NIH report, Bancroft 4 called the statements concerning the etiology of psychogenic ED 'breathtakingly inadequate' and pointed to the lack of knowledge about the mediating mechanisms involved in psychogenic ED, which in his reasoning are also important in cases with known organic diseases. Bancroft's critique highlights the thus far neglected differential aspect of the causation of psychogenic ED, concentrating on the question of why certain psychological risk factors lead to erectile failure in some men and not in others. A proper multistage investigation of this complex field has to start with an appropriate subclassification, allowing a differentiation of the various mechanisms of psychogenic causation. As Lue and Tanagho 5 pointed out, psychogenic ED represents no homogeneous class but rather a syndrome, and they think that a subclassification is urgently needed for differentiating psychogenic from organic erectile failure. As a matter of fact, we have to deal with subtypes of psychogenic EDs, which must be differentiated from subtypes of organic erectile failure.
In the concept of an adequate model of psychogenic ED, Hartmann 3 proceeded from the model of Kaplan and proposed a preliminary model of psychogenic ED. Compared with the Kaplan model, Hartmann's model contains a level of dispositional factors that account for the specific vulnerability of the sexual response system to stress and the associated lability of erection and ejaculation. Additional dispositional factors are ego structural and preoedipal deficits that predispose the patient to an increased tendency for somatization. The following layer of etiological factors is equivalent to the Kaplan model, whereas the level of pathogenetic factors differs from Kaplan's immediate factors. The Hartmann model contains not only the cognitive mechanisms worked out by Barlow and others, but also the defense against the uncontrollable invasion of anxiety, conversion, and dissociation, summarized under the term psychoaffective mechanisms. The model also contains the important psychophysiological mechanisms of a high level of activation and sympathetic tension. The last layer of maintaining factors comprises performance anxiety (which, in my view, means that the process operates in a chronic state rather than as a pathogenetic factor), phobic avoidance of intimate situations, depression, and loss of sexual desire.
A proper subclassification and construction of an adequate model of erectile failure are important steps in the diagnosis of ED, but a number of questions remain. One of the most important questions is how does a certain constellation of risk factors or a sequence of life events finally cause ED? This question addresses the mediating or transmission mechanisms involved in the etiology of erectile failure, which were reviewed herein. There is also the question of different pathogenetic modes of ED. This issue can be viewed from a neurobiological and psychological perspective, which perhaps can be examined some day.
In this article, the psychological perspective has been adopted, and four different pathogenetic modes of psychogenic erectile failure have been distinguished. I believe that erectile failure can be conceptualized as a disturbance of the regulation of a complex system of interacting arousal and inhibition mechanisms involving a variety of psychological and neurobiological variables. According to this notion, emotional or psychological dysregulation can be differentiated from a more vegetativeneuroendocrinological dysregulation. In emotional dysregulations, the initiation and maintenance of sexual arousal are mainly inhibited by different forms of cognitive-affective mechanisms, among which anxiety and its vegetative correlates are of major importance.
The somatic or neuroendocrinological variants seem to directly influence the cavernous myotonus with secondary psychological effects that mainly affect aspects of sexual desire. Another dimension in which these modes have to be classified is their distance to consciousness. The unconscious psychoneurotic and psychosomatic modes can be differentiated from the conscious actual neurotic and functional modes. Using the two axes, the four modes can be tabulated and grouped. Thus, the actual neurotic mode stands for the conscious and the psychoneurotic mode represents the unconscious variant of the emotional dysregulation type. Accordingly, the psychosomatic or psychovegetative variant represents the pathogenetically complicated and unconscious mode of the neurovegetative dysregulation whose conscious counterpart is the functional mode.
Organogenic ED
Currently, ED can be attributed to different distinct organogenic factors. Neurogenic, vascular, smooth muscular, hormonal, and neuropharmacological origins may be the underlying cause of the disease, alone or (often) in combination with psychogenic factors. Intracellular deficiencies have not yet been reported to cause ED.
Neurogenic etiology

Central mechanisms
Because of the high complexity of the human brain, with the involvement of many brain areas in a single body function and, on the other hand, many possible functions being influenced by just one (often the most tiny) area, only sparse information is available regarding central mechanisms of erection. Although the control of penile erection by brainstem nuclei (raphe nuclei) and hypothalamic nuclei (medial preoptic area [MPOA] ) and paraventricular nucleus [PVN]) has been explored using a variety of experimental designs, mainly pharmacological approaches, an integrative view of the central mechanisms of penile erection is lacking. However, these animal experiments and the human comparative studies allow for some conceptual hypotheses. These hypotheses will be corroborated in the near future by cutting edge imaging studies, such as functional magnetic resonance imaging or positron emission tomography, that enable noninvasive examination of central nervous system involvement in the human situation.
Physiological erections are mostly initiated by central stimuli. Depending on the type of stimulus, various areas of the cortex are involved, such as the occipital region for visual, the rhinencephala for olfactory, the thalamic for tactile, and the limbic region for imaginative stimuli. There is good evidence that these and other stimuli from higher centers are sending inputs to the hypothalamic nuclei (MPOA and PVN). The MPOA contains a high density of neurons that concentrate androgens and shows an extensive interconnection to the limbic system and the lower autonomic brainstem nuclei; similarly, the PVN seems to integrate the input from higher centers containing promoter neurons that project directly onto spinal autonomic preganglionic neurons; the PVN is believed to be the nucleus where apomorphine acts as a dopaminergic substance. From the PVN, signals are then transmitted to the brainstem nuclei (periaqueductal gray, nucleus paragigantocellularis and raphe nuclei). 6 As for all other sites of neurotransmission, local traumatic or iatrogenic damage will result in an impairment or complete loss of centrally evoked erections. However, there is growing evidence that defined patient groups show central activation patterns distinctly different from healthy men. 7 Furthermore, the central erectogenic axis depends heavily on an adequate hormonal level, and it can be conceived from animal data 8 that hypogonadism or partial androgen deficit in the aging male impairs central (cerebral and spinal) erections.
Spinal cord and peripheral autonomic fibers
The spinal cord is the source of efferent pathways to the penis and striated perineal muscles. The tonic activity of sympathetic pathways from the thoracolumbar spinal cord keeps the penis flaccid through contraction of penile and artery smooth muscles. The parasympathetic nucleus is located in the sacral spinal cord and elicits erection. Pudendal motoneurons destined to the ischiocavernosus and bulbospongiosus muscles are also present in the sacral spinal cord. 9 Contraction of the ischiocavernosus and bulbospongiosus on the erect penis increases intracavernous and intraspongiosus pressures and augments penile rigidity. In physiological conditions, erection likely occurs when sympathetic, parasympathetic, and somatic pathways coordinate their activity. A classic example of neurogenic ED at the level of the spinal cord is spinal injury. Examples of damages to the peripheral autonomic fibers are pelvic malignancies after radical surgery, such as cystectomy, prostatectomy, or exenteration.
Autonomic neurotransmitters
At the local penile site, erectile function is dependent on the relative balance of activity in these two major transmitter systems. It has been shown in vitro and in vivo (including in humans) that noradrenaline acts as the major sympathetic neurotransmitter, whereas nitric oxide (NO) is the major parasympathetic neurotransmitter. 10, 11 To produce an erection, this balance has to change; the noradrenaline effect must be neutralized and the NO effect enhanced. There is evidence that various peptidergic substances (for example, vasointestinal polypeptide) play a modulatory role in maintaining erection. It has recently been shown that significant disturbances at this local neurotransmitter site can be diagnosed in different patient groups. 12 
Cavernous signal transduction
Comparable to the striated muscle, the amount of intracellular free Ca 2 þ ([Ca 2 þ ]i) is the key to smooth muscle tone regulation. 13, 14 In the resting state, the sarcoplasmatic free Ca 2 þ levels are approximately
Is there a common pathophysiology of ED? CG Stief 120 -270 nM, whereas in the extracellular fluid, the Ca 2 þ levels are in the range of 1.5 -2 mM. This 10 000-fold gradient is maintained by the cell membrane Ca 2 þ pump and the Na þ Ca 2 þ exchanger. Neuronal or hormonal stimulation can open Ca 2 þ channels, resulting in Ca 2 þ entry to the sarcoplasm through its concentration gradient. A rather modest increase of the free sarcoplasmatic Ca 2 þ by a factor of 2 -3 to 550 -700 nM then triggers myosin phosphorylation (see later) and subsequent smooth muscle contraction.
In electromechanical coupling, changes in the sarcoplasmatic Ca 2 þ concentration are caused by changes in the surface membrane potential. Action potentials or long-lasting changes of the resting membrane potential ( 7 40 to 7 70 mV with respect to the extracellular space) depolarize the membrane potential, thus opening the voltage-gated L-type Ca 2 þ channels. 15 Now, Ca 2 þ enters the sarcoplasm driven by the concentration gradient and triggers contraction. Changes in the membrane potential may also be induced by membrane channels other than Ca 2 þ channels. Therefore, different agonists, such as b-adrenergic blocking agents or atriuretic factor, activate potassium channels by involving the intracellular second messenger cyclic guanosine monophosphate (cGMP) or cyclic adenosine monophosphate (cAMP). Up to now, no differences were observed in membrane channels of healthy men vs patients with ED.
Pharmacomechanical coupling mechanisms of smooth muscle relaxation are mediated via the intracellular cyclic nucleotide-protein kinase second messenger system. Via a specific receptor, b-adrenergic blocking agonists activate membranebound adenylate cyclase that generates cAMP. cAMP then activates protein kinase A (and to a lesser extent protein kinase G). The atriuretic factor acts via the membrane-bound guanylate cyclase, whereas NO acts via the soluble form of guanylate cyclase; both generate cGMP, which activates protein kinase G (and to a lesser extend protein kinase A). Both cAMP and cGMP are inactivated by phosphodiesterases (PDEs) by hydrolytic cleavage of the 3 0 -ribose-phosphate bond. Because the distribution and functional role of PDE isoenzymes varies in different tissues, selective inhibitors have the potential to exert (at least partially) specific tissue effects. Currently, more than 55 PDE isoenzymes and isoforms are known. The following PDE isoenzyme and isoform genes were detected in human cavernous tissue: PDE-1A, PDE-1B, PDE-1C, PDE-2, PDE-3A, PDE-4A, PDE-4B, PDE-4C, PDE-4D, PDE-5, PDE-7, PDE-8 and PDE-9. 16 The functional assays revealed a predominant functional role for PDE-3 and PDE-5. 16 When comparing healthy men with patients with severe diabetes and (clinical) smooth muscle myopathy, the PDE distribution pattern of the cavernous smooth muscle cells was comparable in both groups. 16 -19 Cavernous smooth muscle myopathy Although the active role of the cavernous tissue was demonstrated more than a 100 y ago, the view of the phenomenon of erection was rather mechanistic in the sense that erection was regarded as a result of an increase in cavernous arterial inflow and a reduction of cavernous venous outflow. Since the mid-1980s, the crucial role of the cavernous smooth muscle tone has been widely recognized, with the arterial and venous changes being only a secondary phenomenon to changes of the smooth muscle tone. During flaccidity, the cavernous smooth muscles that comprise the wall of the cavernous sinusoids are in a state between full contraction and full relaxation. During erection they relax, resulting in wide sinusoids with a low peripheral resistance and a consecutive inflow increase; venous restriction is achieved by passive compression of the venules between the tunica albuginea and the expanding cavernous tissue. 5, 20 During an elevated a-tone (stress, anxiety, cold), cavernous smooth muscles fully contract; an elevated a-tone may inhibit erections in an otherwise healthy man (for example, psychogenic impotence evoked by performance anxiety). 21, 22 Electron microscopic and histomorphologic studies showed cavernous smooth muscle degeneration to be a major cause of ED, 23 especially in patients with long-standing diabetes mellitus. Another cause of cavernous myopathy may be hypogonadism, since animal studies showed cavernous smooth muscle apoptosis after androgen withdrawal. 8 
Vascular etiology
The arterial supply of the cavernous bodies emerges from the internal iliac arteries, then runs via the pudendal artery to the branching of the penile arteries, the dorsal and cavernous arteries. This classic penile arterial supply varies considerably, thus being a pitfall for interpretation of selective arteriograms.
However, most young patients undergoing highvelocity car or motorcycle crashes with complex pelvic fractures and secondary ED will show localized rupture of the pudendal artery at the level of the pelvic floor, which is typical in cases with arterial origins (in virtually every case combined with disruption of the autonomic supply). 24 Generalized arteriopathy was shown after severe imbalances of blood fatty acids. 25 In patients with chronic diabetes, both macroangiopathy and microangiopathy were cofactors for the patients' ED. 23 
Conclusions
It is well established that both psychogenic and organogenic causes of ED can be subdivided into several well-distinguishable origins. Depending on the specific cause or (in most patients) the specific pattern of mixed causes in an individual patient, the chances of success of a therapeutic option and the spectrum of possible adverse effects will vary enormously. Therefore, a young man who has undergone non-nerve-sparing radical prostatectomy will not benefit from oral pharmacotherapy but most likely will benefit from local pharmacotherapy. A patient with chronic diabetes and end-stage cavernous myopathy will not benefit from any form of pharmacotherapy and will require intrapenile or extrapenile mechanical aids. Hypogonadal men should not be treated symptomatically but rather with hormonal replacement. Patients with performance anxiety may benefit from a-adrenergic blocking agents, whereas such patients with mild to moderate myogenic or any form of arteriogenic disease probably require a central initiator or peripheral conditioner. Severe forms of myogenic and=or arteriogenic ED will need intracavernous pharmacotherapy, since they probably need maximal pharmacological stimulation to induce sufficient smooth muscle relaxation (or will combination therapy of a central initiator plus a peripheral conditioner suffice?).
These examples illustrate that different treatment strategies are necessary in the treatment of ED because of the wide range of possible and often mixed origins of the disease. An often proclaimed 'ideal drug' or 'ideal therapy' thus cannot exist in such a complex disease. Furthermore, these few cases show that adequate therapy requires appropriate diagnosis and that the often used trial-anderror approach (euphemistically also called goaloriented approach) is inadequate in many patients, although it may induce sufficient erections.
prostatectomies, there seems to be a point where we have the induction of such a large amount of apoptosis that at least pharmacologically we will not be able to treat these people any more. Therefore, you recognize this effect and start to treat patients early after radical prostatectomies. Dr Meuleman: Talking about short-term symptomatic treatments, do you see any possibilities to have more structural treatments that can reverse pathological processes that are involved? Dr Stief: We have to shift or at least try to shift from symptomatic treatment to really cure the patients. Human growth hormone may be a future therapeutic goal for gene therapy. However, at the moment, since we are missing so much information on central integration and spinal processing, we still have probably a decade or two decades of symptomatic pharmacological treatments ahead of us. Dr Porst: I personally have some problems with human growth hormone because it's proven that patients with prostate cancer have an elevated insulin-like growth factor, which is dependent on growth hormone release. So in the future when we are treating patients with human growth hormone, we may be inducing more prostate cancer. Dr Stief: Even with dopaminergic agonists, amelanocyte-stimulating hormone, or phosphodiesterase inhibitors, nobody really knows what this does in the long run in other tissues in neoplasm induction or prevention. We just have to be open and try it. Dr Pryor: Talking about ED now, I think it emphasizes two other points. One is to bring to the public's awareness those risk factors that can be modified so that the patient doesn't get ED, for example, smoking and control of diabetes. The other is to get the patients to present early rather than late because the longer you go with your ED, the more difficult it is to reverse. Dr Hatzichristou: The difficult point is in patients who already have organic ED. For these patients, we're not talking about reversing ED but rather treating it at an early stage. Because if a patient has a history of long-lasting ED, he is more likely to have a more severe form of ED and probably he will be a nonresponder to whatever treatment we try. Dr Hedlund: We know we have to prevent apoptosis in patients with diabetes. We know that we may consider the effect of growth factors. But we now have a huge population of aging men. Can you suggest how we can prevent ED in a patient in whom the substitution of hormones will not help the decreasing effect on the nerves? Dr Stief: I think healthy erection corresponds to a healthy cardiovascular status. Prevention will be a big emphasis. I think testosterone replacement in one form or another will be a big hit in the future. We are just missing good epidemiological data on whom to replace, at what time, and at what level. We will probably experiment with a lot of other factors, such as what growth hormone to use and nerve trophic factors, because we are now beginning to understand the diversity and the complexity of the phenomenon.
